Erratum: Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
- PMID: 28174493
- PMCID: PMC5261548
- DOI: 10.2147/CEOR.S118835
Erratum: Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Abstract
[This corrects the article on p. 227 in vol. 8, PMID: 27284260.].
Erratum for
-
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey.Clinicoecon Outcomes Res. 2016 May 23;8:227-33. doi: 10.2147/CEOR.S97319. eCollection 2016. Clinicoecon Outcomes Res. 2016. PMID: 27284260 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources